pyridostigmine bromide 12 MG/ML Oral Solution

What the CMS Formulary Data Shows for pyridostigmine bromide 12 MG/ML Oral Solution

Per the CMS 2026 Part D formulary file, pyridostigmine bromide 12 MG/ML Oral Solution (RxNorm concept RXCUI 903843, generic name pyridostigmine bromide) appears on 42 distinct formulary files spanning 609 Medicare Part D plan offerings - 12.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 3.

Real-world access to pyridostigmine bromide 12 MG/ML Oral Solution depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 56,300 Part D beneficiaries filled pyridostigmine bromide 12 MG/ML Oral Solution in 2023, with total plan-and-beneficiary spending of $25,410,334 and an average per-beneficiary annual cost of $451.34. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry pyridostigmine bromide 12 MG/ML Oral Solution today.